Trial reportMedical science monitor : international medical journal of experimental and clinical research2025
Comparative Efficacy of Remimazolam Versus Propofol in Meningioma Surgery with Scalp Nerve Block.
Trial report in Medical science monitor : international medical journal of experimental and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND This study aimed to evaluate the advantages of remimazolam combined with selective scalp nerve block in patients undergoing craniotomy for meningioma. MATERIAL AND METHODS A total of 300 patients undergoing craniotomy for meningioma were enrolled and randomly assigned to either the control group (n=150, propofol + selective scalp nerve block) or the experimental group (n=150, remimazolam + selective scalp nerve block). Hemodynamic parameters, pain intensity, central nervous system-specific protein levels (S100-beta protein [S100-b]), inflammatory markers, and the incidence of adverse reactions were recorded and compared at multiple postoperative time points. RESULTS Visual analog scale scores, S100-ß levels, and levels of inflammatory factors - interleukin-6, tumor necrosis factor-alpha, and C-reactive protein - were significantly lower in the experimental group than in the control group at 2, 8, 12, and 24 h postoperatively (all P<0.05). The incidence of adverse reactions was significantly lower in the experimental group (2.67%) than in the control group (13.33%) (P<0.05). Although systolic blood pressure, diastolic blood pressure, and heart rate decreased after anesthesia induction in both groups, the experimental group exhibited more stable hemodynamic profiles (all P<0.05). CONCLUSIONS Remimazolam combined with selective scalp nerve block enhances analgesia, reduces brain injury and inflammatory markers, lowers the incidence of adverse effects, and provides more stable intraoperative hemodynamics in patients undergoing craniotomy for meningioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.